NASDAQ:MRUSMerus Stock Price, Forecast & News

Merus' stock was trading at $14.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MRUS stock has decreased by 6.1% and is now trading at $13.65. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merus.

Merus is scheduled to release its next quarterly earnings announcement on Monday, August 17th 2020. View our earnings forecast for Merus.

Merus NV (NASDAQ:MRUS) issued its quarterly earnings data on Thursday, March, 12th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.60. The biotechnology company had revenue of $7.09 million for the quarter, compared to analysts' expectations of $9.12 million. Merus had a negative return on equity of 62.96% and a negative net margin of 225.21%. View Merus' earnings history.

3 brokers have issued 12-month target prices for Merus' stock. Their forecasts range from $16.00 to $23.00. On average, they expect Merus' share price to reach $19.67 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price. View analysts' price targets for Merus.

Media stories about MRUS stock have trended very negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merus earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutMerus.

Merus saw a increase in short interest in May. As of May 15th, there was short interest totaling 227,600 shares, an increase of 6.1% from the April 30th total of 214,600 shares. Based on an average daily volume of 99,300 shares, the short-interest ratio is presently 2.3 days. Currently, 1.2% of the company's stock are sold short. View Merus' Current Options Chain.

Some companies that are related to Merus include Ironwood Pharmaceuticals (IRWD), Opko Health (OPK), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), Akebia Therapeutics (AKBA), ZEALAND PHARMA/S (ZEAL), CytoDyn (CYDY), Akcea Therapeutics (AKCA), Constellation Pharmaceuticals (CNST), Amneal Pharmaceuticals (AMRX), Arcus Biosciences (RCUS), Phoenix Tree (IMAB), Innoviva (INVA), Portola Pharmaceuticals (PTLA) and Intra-Cellular Therapies (ITCI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Exelixis (EXEL), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP) and Fate Therapeutics (FATE).

(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Merus' stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (6.25%), Driehaus Capital Management LLC (4.64%), Wellington Management Group LLP (2.91%), Cormorant Asset Management LP (2.07%), Morgan Stanley (0.57%) and Alps Advisors Inc. (0.18%). Company insiders that own Merus stock include Bvf Partners L P/Il, Mark Throsby and Value Fund L P Biotechnology. View institutional ownership trends for Merus.

MRUS stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Driehaus Capital Management LLC, Wellington Management Group LLP, Two Sigma Investments LP, Alps Advisors Inc., Athanor Capital LP, and Weiss Multi Strategy Advisers LLC. View insider buying and selling activity for Merus.

MRUS stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Morgan Stanley, Two Sigma Advisers LP, and Global Retirement Partners LLC. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Merus.

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRUS stock can currently be purchased for approximately $13.65.

Merus has a market capitalization of $396.40 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Merus employs 98 workers across the globe.

The official website for Merus is www.merus.nl.

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]